Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

During embryonic development, the intestine of the Drosophila fly divides into distinct chambers thanks to the formation of ...

This important study provides solid evidence that glucosylceramide synthase (GlcT), a rate-limiting enzyme for glycosphingolipid (GSL) production, plays a role in the differentiation of intestinal ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer. Tremelimumab ...

The field of cancer immunotherapy was revitalized after impressive successful experiences with introducing ipilimumab as anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibodies and ...